Matinas BioPharma Announces Executive and Director Changes

Ticker: MTNB · Form: 8-K · Filed: Nov 21, 2025 · CIK: 1582554

Matinas Biopharma Holdings, Inc. 8-K Filing Summary
FieldDetail
CompanyMatinas Biopharma Holdings, Inc. (MTNB)
Form Type8-K
Filed DateNov 21, 2025
Risk Levelmedium
Pages1
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: management-change, executive-compensation, board-of-directors

TL;DR

Matinas BioPharma shakes up board and exec pay - new faces, new deals.

AI Summary

Matinas BioPharma Holdings, Inc. announced on November 18, 2025, changes in its board and executive compensation. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for its officers.

Why It Matters

Changes in leadership and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in directors and officers, especially without detailed explanations, can introduce uncertainty about the company's future direction and stability.

Key Players & Entities

  • Matinas BioPharma Holdings, Inc. (company) — Registrant
  • November 18, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • Bedminster, New Jersey (location) — Principal executive offices

FAQ

Who are the specific directors or officers that have departed from Matinas BioPharma?

The filing indicates the departure of certain officers and directors but does not name them specifically in the provided text.

When did the reported changes in directors and officers take effect?

The earliest event reported for these changes is November 18, 2025.

What are the key details of the new compensatory arrangements for officers?

The filing mentions adjustments to compensatory arrangements but does not provide specific details on these arrangements in the provided text.

Are there any new directors elected to the board?

Yes, the filing states the election of directors as an item of information.

What is the principal executive office address for Matinas BioPharma?

The principal executive offices are located at 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921.

Filing Stats: 433 words · 2 min read · ~1 pages · Grade level 12 · Accepted 2025-11-21 17:15:34

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MATINAS BIOPHARMA HOLDINGS, INC. Dated: November 21, 2025 By: /s/ Jerome D. Jabbour Name: Jerome D. Jabbour Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.